Showing session: reset
Clinical Trials of Combinations of Molecularly Targeted and Non-targeted Therapeutic Agents
- Sort by:
- Browse by:
- Free
- audio + slides
- Some slides withheld
Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer
Jan H. M. Schellens
The Netherlands Cancer Institute, Amsterdam, Netherlands
- Free
- audio + slides
- Some slides withheld
Discussant
Jordan D. Berlin
Vanderbilt-Ingram Cancer Center, Nashville, TN, United States
- Free
- slides video
- audio + slides
- All slides included
Translating preclinical observations to the clinic: Combination of the dual m-TORC1/2 inhibitor AZD2014 and paclitaxel in ovarian and lung cancer
Udai Banerji
Inst. of Cancer Research and The Royal Marsden, London, United Kingdom
- Free
- slides video
- audio + slides
- All slides included
Discussant
Philippe L Bedard
Univ. of Toronto Univ. Health Network, Toronto, ON, Canada
- Free
- slides video
- audio + slides
- All slides included
Phase I study of GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine in patients with refractory solid tumors
Jeffrey R. Infante
Sarah Cannon Research Institute, Nashville, TN, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Gary K. Schwartz
Columbia University Irving Comp. Cancer Center, New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
Combination of agonistic CD40 monoclonal antibody CP-870,893 and anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma
David L Bajor
University of Pennsylvania, Philadelphia, PA, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Paul B. Chapman
Memorial Sloan Kettering Cancer Center, New York, NY, United States